Larvol Delta - Improvements-in-SLE-Disease-Activity-Across-Multiple-Organ-Systems-with-Intravenous-and-Subcutaneous-Anifrolumab-Treatment-Pooled-Analysis-of-3-Phase-3-Trials

Saphnelo (anifrolumab-fnia) - AstraZeneca

https://acrconvergence2026.eventscribe.net/fsPopup.asp?PresentationID=1898731&mode=presInfo

Richard A. Furie, MD, MACR

Sep 8, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Prev Next